26 June 2025
Geneva – The Medicines Patent Pool (MPP) is proud to publish today its 2024 annual report, Breaking New Ground. The report demonstrates that MPP continues to bring positive change for millions of people in low- and middle-income countries (LMICs) across the globe.
Access MPP’s 2024 Annual Report
As well as a significant expansion in treatment uptake, economic savings and health benefits, 2024 also saw the launch of MPP’s Value Project, which quantifies the benefits of MPP’s licences for originator companies. This is now being widely disseminated within the pharmaceutical industry as a way of engaging with them to share the many benefits of voluntary licensing, with a view to encouraging more licences.
Charles Gore, MPP’s Executive Director said: “The wider geopolitical context of conflict, polarisation and development aid cuts is seeing a significant detrimental impact on global health. But throughout 2024 MPP remained focused on its core objectives, resulting in a positive impact in enabling more affordable and high-quality health products for LMICs.
Since 2010, MPP has supplied over 52 billion doses of treatment through its licences, generating saving of US$ 2.3 billion to the international community. And because of MPP’s licence and the generic competition it creates, treatment for HIV consisting of tenofovir, lamivudine and dolutegravir (TLD) in a single daily tablet is now available at around $US 37 per person per year or about 10 cents per tablet.”
The figures below show that the UN-backed organisation has made remarkable progress since its inception in 2010 to the end of 2024:
Media Contact: Gelise McCullough Director of Communications, Medicines Patent Pool gmccullough@medicinespatentpool.org +41 79 685 64 36
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.